Innovent Biologics (Suzhou) Co. Ltd.: Phase 3 study in Locally Advanced Rectal Cancer (500 participants)
Innovent Biologics (Suzhou) Co. Ltd.: Phase 3 study in Locally Advanced Rectal Cancer (500 participants). Its enrollment of 500 is top-decile (90th percentile of 9,177 records). Dated 2 days ago, it is inside the fresh trigger window. Score 100/100. As of 2026-11-05, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 500 · 90th percentile of 9,177 ClinicalTrialStartPulse records · 6.3x the median
Free preview: all 14 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Innovent Biologics (Suzhou) Co. Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Sintilimab Combined With LCCRT Followed by Capeox Chemotherapy in pMMR/MSS/MSI-L Locally Advanced Rectal Cancer |
| NCT ID | NCT07917468 |
| Phase | Phase 3 |
| Status | not yet recruiting |
| Conditions | Locally Advanced Rectal Cancer |
| Intervention types | drug, radiation, procedure |
| Target enrollment | 500 |
| Site countries | China |
| Posted | 2026-11-04 |
| Planned start | 2026-11-25 |
| Event | Newly registered study |
| Event date | 2026-11-04 |
| enrollment percentile | 90th of 9,177 (median 80, 6.3x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Innovent Biologics (Suzhou) Co. Ltd.
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Free first: a 10-record sample of records
See the real columns before you buy. One confirmation email, nothing else unless you opt in.
Unlock Innovent Biologics (Suzhou) Co + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-11-04
- Data refreshed: 2026-11-05
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Thu, 05 Nov 2026 08:46:16 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Innovent Biologics (Suzhou) Co. Ltd. and 6,823 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,823
- Innovent Biologics (Suzhou) Co. Ltd.'s enrollment: 90th percentile of 9,177 records
- Timing: High: dated in the last 7 days
- Estimated pipeline if you contact every NONUS peer: $1,364,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
100 / 100 Score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Phase 3: multi-site, larger budget.
- 500 participants planned.
- Not yet recruiting: vendors still being chosen.
What is the ClinicalTrialStartPulse record for Innovent Biologics (Suzhou) Co. Ltd.?
Innovent Biologics (Suzhou) Co. Ltd. registered a Phase 3 study (NCT07917468) in Locally Advanced Rectal Cancer targeting 500 participants, posted 2026-11-04.
How does Innovent Biologics (Suzhou) Co. Ltd. compare to other ClinicalTrialStartPulse records?
This is a top-decile record: its enrollment of 500 is 6.3x the median of 80 across 9,177 records. It is fresh: dated 2 days ago, inside the window where early outreach matters most. Its Score of 100/100 puts it among the stronger signals in this feed.
Innovent Biologics (Suzhou) Co. Ltd. vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Innovent Biologics (Suzhou) Co. Ltd. | NONUS | 500 | 90th | 2026-11-04 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NONUS | 420 | 88th | 2026-11-04 |
| GlaxoSmithKline | NONUS | 610 | 91st | 2026-11-03 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | NONUS | 144 | 69th | 2026-11-04 |
Related records
- NervGen Pharma
- Biogen
- Teva Branded Pharmaceutical Products R&D LLC
- Eli Lilly and Company
- Arcutis Biotherapeutics, Inc.
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Stemline Therapeutics, Inc.
- AstraZeneca
- Teva Branded Pharmaceutical Products R&D LLC
- Genmab
- GlaxoSmithKline
ClinicalTrialStartPulse: Phase 3 ClinicalTrialStartPulse: Outside the US only
How to monitor Innovent Biologics (Suzhou) Co. Ltd. and peer phase 3 records
Get new ClinicalTrialStartPulse records like Innovent Biologics (Suzhou) Co. Ltd. by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.